Product Description
| Brand | Zybio |
| Sample Type | Plasma |
| Pack Size | 2 x 50T |
| CAT No | 0601901 |
Application | Tumor Marker |
ZYBIO CLIA Cancer Antigen 15-3 (CA 15-3)Â reagent kit is designed for accurate quantitative determination of CA 15-3 levels using chemiluminescent immunoassay technology. CA 15-3 reagent is a clinically important tumor marker that is primarily used to monitor patients with metastatic or recurrent breast cancer and to assess disease progression.Advanced CLIA Technology for Enhanced DetectionThe ZYBIO EXI leverages Chemiluminescence Immunoassay (CLIA) technology, ensuring sensitive and accurate quantification of the CA 15-3 antigen. This system streamlines laboratory workflows with its automatic, real-time operation, making it a trusted choice for professional diagnostic environments.
Portability and Ease of UseDesigned with portability in mind, this CLIA analyzer can be easily transported or relocated within medical laboratories. Its user-friendly automatic operation reduces the need for extensive training, enabling laboratories to perform CA 15-3 determinations efficiently.
Reliable Solution for Cancer MonitoringBy enabling timely and precise measurement of Cancer Antigen 15-3 levels, the ZYBIO EXI supports clinicians in the ongoing assessment and management of cancer patients. It contributes to improved decision-making regarding disease progression and treatment efficacy.
FAQ's of ZYBIO EXI Cancer Antigen 15-3 [CA 15-3] (CLIA):
Q: How does the ZYBIO EXI CA 15-3 CLIA Analyzer work?
A: The ZYBIO EXI uses chemiluminescence immunoassay (CLIA) technology to detect and measure the CA 15-3 cancer antigen in patient samples. The analyzer automates the testing process, providing real-time, quantitative results for laboratory professionals.
Q: What is the main benefit of using a CLIA-based analyzer for CA 15-3 determination?
A: A CLIA-based analyzer offers enhanced sensitivity and accuracy in biomarker detection, making it especially valuable for monitoring cancer progression and response to therapy. Real-time results support quicker clinical decision-making.
Q: When should CA 15-3 testing be performed using this equipment?
A: CA 15-3 testing is typically conducted in laboratory settings as part of the monitoring and management protocol for patients with certain cancers, particularly breast cancer. The test can be used during diagnosis or follow-up visits as needed by the clinician.
Q: Where is the ZYBIO EXI Analyzer commonly used?
A: This analyzer is intended for use in professional medical laboratories, hospitals, and diagnostic centers across India. Its portable design allows for flexibility within these settings, although it is not wall mounted.
Q: What is the process for operating the ZYBIO EXI Analyzer?
A: Operation involves loading the patient sample, initiating the automatic run via the device interface, and retrieving results in real time. The system is fully automated, reducing manual intervention and potential errors.
Q: How should the analyzer be stored to maintain optimal performance?
A: The analyzer and its reagents should be stored at temperatures between 2 and 8 degrees Celsius. Adhering to these storage guidelines helps preserve reagent integrity and ensures precise test outcomes.
Q: Who can supply the ZYBIO EXI CA 15-3 CLIA Analyzer in India?
A: Authorized dealers, distributors, exporters, manufacturers, suppliers, traders, and wholesalers throughout India are equipped to provide the ZYBIO EXI CLIA Analyzer, ensuring broad accessibility and reliable support for laboratories.